Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant CancersTimothy A. Yap, Johann S. de Bono, Rebecca Kristeleit et al.|Cancer Discovery|2020Cited by 134
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Nicholas C. Turner, Isaac García-Murillas et al.|Cancer Discovery|2020Cited by 67
Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot StudyRaghav Sundar, Einar Wilder‐Smith, Aishwarya Bandla et al.|Frontiers in Oncology|2017Cited by 56
The role of limb hypothermia in preventing paclitaxel-induced peripheral neuropathy.Raghav Sundar, Einar Wilder‐Smith, Aishwarya Bandla et al.|Journal of Clinical Oncology|2016Cited by 2